What one share of Sarepta Therapeutics holds
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.58 |
|---|---|
| Profit | −$0.86 |
| Capex (buildings and equipment) | $0.26 |
| Free cash flow | $0.73 |
| Cash and investments | $5.41 |
| Debt | $8.02 |
| Book value | $14.46 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | — | −$1.62 | $0.06 | −$0.63 | — | $1.52 |
| 2010 | — | −$1.74 | $0.04 | −$0.87 | — | −$0.15 |
| 2011 | — | −$0.12 | $0.05 | −$1.15 | — | $1.37 |
| 2012 | — | −$5.14 | $0.00 | −$1.26 | — | $3.90 |
| 2013 | — | −$3.31 | $0.07 | −$1.98 | — | $6.55 |
| 2014 | $0.24 | −$3.39 | $0.64 | −$3.85 | — | $5.99 |
| 2015 | $0.03 | −$5.20 | $0.08 | −$3.61 | — | $4.17 |
| 2016 | $0.11 | −$5.49 | $0.11 | −$5.16 | — | $6.15 |
| 2017 | $2.63 | −$0.86 | $0.20 | −$4.15 | — | $12.18 |
| 2018 | $4.54 | −$5.46 | $0.92 | −$6.79 | — | $14.52 |
| 2019 | $5.17 | −$9.71 | $0.81 | −$7.01 | — | $10.88 |
| 2020 | $6.93 | −$7.11 | $1.05 | $0.32 | — | $9.60 |
| 2021 | $8.64 | −$5.15 | $0.47 | −$5.93 | — | $10.65 |
| 2022 | $10.66 | −$8.03 | $0.35 | −$4.07 | — | $4.38 |
| 2023 | $13.46 | −$5.80 | $0.82 | −$6.25 | — | $9.17 |
| 2024 | $17.63 | $2.34 | $1.27 | −$3.18 | — | $15.77 |
| 2025 | $21.96 | −$7.13 | $1.02 | −$3.07 | — | $10.87 |
Common questions about Sarepta Therapeutics
How much does one share of Sarepta Therapeutics earn?
Over the last 12 months, Sarepta Therapeutics lost $0.86 for each share on $17.58 of sales.
Does Sarepta Therapeutics pay a dividend?
Sarepta Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Sarepta Therapeutics’s book value per share?
Sarepta Therapeutics’s book value is $14.46 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Sarepta Therapeutics have?
Each share of Sarepta Therapeutics has $5.41 of cash and investments and $8.02 of debt, as of June 30, 2026.
What is Sarepta Therapeutics’s free cash flow per share?
$0.73 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Sarepta Therapeutics bought back shares?
Sarepta Therapeutics’s share count rose about 545% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.